LAD328

DRUG2 trials

Sponsors

Almirall S.A., Almirall, S.A.

Conditions

Hidradenitis Suppurativamoderate-to-severe hidradenitis suppurativa

Phase 2

A Phase 2, randomized, placebo-controlled, double-blind clinical study to evaluate efficacy and safety of LAD328 in adult subjects with moderate to severe hidradenitis suppurativa

Not yet recruitingCTIS2025-521865-29-00

Almirall S.A.moderate-to-severe hidradenitis suppurativa

Target: 3999996Updated: 2026-04-02

A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa

RecruitingNCT07547813

Almirall, S.A.Hidradenitis Suppurativa

Start: 2026-05-13End: 2027-04-01Target: 50Updated: 2026-08-17